We are live on ! Find out more
HMC

Harvard Management Company Portfolio holdings

AUM $1.82B
1-Year Est. Return 26.23%
This Fund
S&P 500
This Quarter Est. Return
-20.88%
1 Year Est. Return
+26.23%
3 Year Est. Return
+156.3%
5 Year Est. Return
+133.98%
10 Year Est. Return
+221.37%
AUM
$991M
AUM Growth
-$74.7M
Cap. Flow
+$164M
Cap. Flow %
16.57%
Top 10 Hldgs %
82.31%
Holding
48
New
2
Increased
4
Reduced
–
Closed
4

Top Buys

Rank Stock Value
1
META icon
Meta Platforms (Facebook)
META
+$215M
2
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$70.8M
3
PCT icon
PureCycle Technologies
PCT
+$10.4M
4
GRAB icon
Grab
GRAB
+$8.52M
5
VIGL
Vigil Neuroscience
VIGL
+$3.82M

Top Sells

Rank Stock Value
1
RPRX icon
Royalty Pharma
RPRX
+$138M
2
ASML icon
ASML
ASML
+$7.19M
3
DADA
Dada Nexus
DADA
+$531K
4
SRZNW icon
Surrozen Inc Warrant
SRZNW
+$125K

Sector Composition

Rank Sector Weight
1 Communication Services 52.08%
2 Healthcare 19.11%
3 Consumer Discretionary 15.88%
4 Technology 8.04%
5 Industrials 2.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QRVO icon
26
Qorvo
QRVO
$8.41B
$5.83M 0.59%
46,963
– –
KNTE
27
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$5.61M 0.57%
498,001
– –
TNGX icon
28
Tango Therapeutics
TNGX
$4.72B
$5.37M 0.54%
708,385
– –
CFLT
29
DELISTED
Confluent
CFLT
$5.35M 0.54%
130,383
– –
NRIX icon
30
Nurix Therapeutics
NRIX
$2.62B
$4.41M 0.45%
314,762
– –
PLRX icon
31
Pliant Therapeutics
PLRX
$65M
$3.94M 0.4%
562,379
– –
SANA icon
32
Sana Biotechnology
SANA
$949M
$3.87M 0.39%
468,749
– –
GBIO
33
DELISTED
Generation Bio
GBIO
$3.75M 0.38%
51,035
– –
XLO icon
34
Xilio Therapeutics
XLO
$61M
$2.94M 0.3%
29,719
– –
PRDS
35
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$2.89M 0.29%
400,000
– –
SRZN icon
36
Surrozen
SRZN
$251M
$2.49M 0.25%
55,123
– –
PACB icon
37
Pacific Biosciences
PACB
$363M
$2.08M 0.21%
229,144
– –
PCTTW
38
PureCycle Technologies Inc Warrant
PCTTW
$2.05M 0.21%
+714,285
New +$1.84M
VIGL
39
DELISTED
Vigil Neuroscience
VIGL
$2.04M 0.21%
+289,460
New +$3.82M
DYN icon
40
Dyne Therapeutics
DYN
$4.83B
$1.03M 0.1%
107,252
– –
DBTX
41
DELISTED
Decibel Therapeutics, Inc. Common Stock
DBTX
$1M 0.1%
328,798
– –
DNTH icon
42
Dianthus Therapeutics
DNTH
$6.15B
$965K 0.1%
20,788
– –
MCRB icon
43
Seres Therapeutics
MCRB
$47.9M
$939K 0.09%
6,592
– –
IRON icon
44
Disc Medicine
IRON
$2.97B
$348K 0.04%
8,333
– –
ASML icon
45
ASML
ASML
$655B
– –
-9,034
Closed -$7.19M
DADA
46
DELISTED
Dada Nexus
DADA
– –
-40,338
Closed -$531K
RPRX icon
47
Royalty Pharma
RPRX
$25.4B
– –
-3,464,990
Closed -$138M
SRZNW icon
48
Surrozen Inc Warrant
SRZNW
$22.4K
– –
-108,333
Closed -$125K
1
2

Similar funds

DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $1.82B AUM 19.69% 1-Year Est. Return
SI
Standard Investments New York $1.83B AUM 4.12% 1-Year Est. Return
GC
Gobi Capital San Francisco, California $1.8B AUM 7.28% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
KAM
Kensington Asset Management Austin, Texas $1.84B AUM 13.95% 1-Year Est. Return
OQS
Occudo Quantitative Strategies Fort Lauderdale, Florida $1.84B AUM 22.15% 1-Year Est. Return
RP
Regal Partners Sydney, NSW, Australia $1.84B AUM 54.78% 1-Year Est. Return
BP
BBR Partners New York $1.79B AUM 16.83% 1-Year Est. Return

Harvard Management Company's Q1 2022 Portfolio in Review

As of Q1 2022, Harvard Management Company held 48 positions worth $991M, down 7% from $1.07B the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Harvard Management Company deployed $164M of net new capital in Q1 2022, opening 2 new positions and adding to 4 existing holdings. Its largest new stake was Vigil Neuroscience: 289,460 shares worth $2.04M.

By sector, the portfolio is most concentrated in Communication Services at 52% of assets, up from 28% a quarter earlier, followed by Healthcare and Consumer Discretionary.

On the sell side, the most notable exit was Royalty Pharma, an estimated $138M sold.

  • Harvard Management Company's largest Q1 2022 buy was Vigil Neuroscience: 289,460 shares worth $2.04M.
  • Harvard Management Company added most to Meta Platforms (Facebook) in Q1 2022, an estimated $215M increase.
  • Harvard Management Company fully exited Royalty Pharma in Q1 2022, selling an estimated $138M.
  • Harvard Management Company's ten largest holdings make up 82% of its $991M portfolio in Q1 2022.
  • Harvard Management Company opened 2 new positions and closed 4 in Q1 2022.
  • Harvard Management Company's portfolio value fell 7% quarter-over-quarter to $991M.

Based on Harvard Management Company's 13F filing for Q1 2022, filed 13 May 2022.